oxy-Arachidonoyl Ethanolamide (Synonyms: oxyAEA, oxyAnandamide) |
| Katalog-Nr.GC44522 |
AEA acts as an endogenous mimic of δ9-THC, the psychotropic component of marijuana.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 883296-70-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AEA acts as an endogenous mimic of δ9-THC, the psychotropic component of marijuana. oxy-AEA is the O-alkyl-N-acyl oxyhomologue of AEA. oxy-AEA is selective for the peripheral cannabinoid (CB2) receptor with Ki values of 0.47 and 0.081 µM for hCB1 and hCB2, respectively. In comparison, AEA has a greater affinity for the central cannabinoid (CB1) receptor with Ki values of 0.07 and 0.18 µM for hCB1 and hCB2, respectively. oxy-AEA is the first known fatty acid amide with a reversed CB1/CB2 affinity ratio.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *